Dudediligence.

UroGen Pharma Ltd

URGNNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

48.9M

on 2026-06-30, from 36.1M on 2024-03-31 10-Q ↗

20M40MMar2024JunSepDecMar2025JunSepDecMar2026Jun

Newest

No limit

S-3ASR of 2025-11-06. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗

$75.0M

TD Securities (USA), agreement of 2019-12-20. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗

Warrants

The 10-Q filed 2026-08-05 is not read yet.

Cash

2.8 quarters

$109.3M on 2026-06-30 ÷ $39.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 6 of its filings are not read yet.

Also on file: up to $250.0M term loans agreed 2026-02-26 8-K ↗